Female infertility: treatment options for complicated cases. The ESHRE Capri Workshop. European Society for Human Reproduction and Embryology

The prevalence of myopia is increasing extensively worldwide. The number of people with myopia in 2020 is predicted to be 2.6 billion globally, which is expected to rise up to 4.9 billion by 2050, unless preventive actions and interventions are taken. The number of individuals with high myopia is also increasing substantially and pathological myopia is predicted to become the most common cause of irreversible vision impairment and blindness worldwide and also in Europe. These prevalence estimates indicate the importance of reducing the burden of myopia by means of myopia control interventions to prevent myopia onset and to slow down myopia progression. Due to the urgency of the situation, the European Society of Ophthalmology decided to publish this update of the current information and guidance on management of myopia. The pathogenesis and genetics of myopia are also summarized and epidemiology, risk factors, preventive and treatment options are discussed in details.

Download Full-text

O-034 Infertility treatment law making in Europe: the clash of knowledge, ethics and business

Human Reproduction ◽

10.1093/humrep/deab126.033 ◽

2021 ◽

Vol 36 (Supplement_1) ◽

Author(s):

A Wilinska-Zelek

Keyword(s):

Genetic Diagnosis ◽

Medical Knowledge ◽

Infertility Treatment ◽

Oocyte Donation ◽

European Countries ◽

Human Reproduction ◽

Main Concern ◽

Eligibility Criteria ◽

The Law ◽

Law Making

Abstract text Infertility treatment law making in Europe: the clash of knowledge, ethics and business Today, there is no common European set of rules for Assisted Reproduction Technology (ART). ART is now controlled by legislation in almost all European countries, substantial variations exist within the detail of that legislation. Main legal differences between countries relate to: embryo selection, particularly by genetic screening, embryo freezing and embryo transfer, preimplantation genetic diagnosis (PGD), oocyte donation, anonymity of gamete donors, surrogacy, patient eligibility criteria (eg, sexual orientation, age), reimbursement and state funding. The most complete survey ever of the ART legal and funding framework of 43 European countries was published in the ESHRE medical journal Human Reproduction Open: Calhaz-Jorge C, De Geyter C, Kupka MS, et al. Survey on ART and IUI: Legislation, regulation, funding and registries in European countries. Hum Reprod Open 2020; doi:10.1093/hropen/hoz044. Unfortunately, changes of legislation are so dynamic that much of the information in this article is no longer up-to-date. Lawyers observe that one of the most important rule of law “When the Law ceases to reflect the realities of Life, it is the Law that will Change” does not work in ART. In regard to this matter dominant rule is: “The Law will change only when it ceases to reflect the government’s point of view and lobbyists’ needs”. Modern medical knowledge and the society’s needs are often not the main concern during the law making discussion. The speech discusses the issues related to infertility treatment law making in Europe with a focus of the problem that modern medical knowledge in this process is not taken into account at all. The author diagnoses numerous problem related to determining the border between medical knowledge, ethics and business in law making process. The observed problems will be discussed on selected examples (from Poland, Greece and the United Kingdom) during presentation at the ESHRE on-line 37th Annual Meeting.

Download Full-text

A long-acting repeatable form of bromocriptine as long-term treatment of prolactin-secreting macroadenomas: a multicenter study†‡Supported by Sandoz Pharma, Ltd.†Presented in part at the Joint Meeting of the European Society of Human Reproduction and Embryology and the European Sterility Congress Organization, Milan, Italy, August 31, 1990.‡The following investigators were participants in this French multicenter study: Philippe Jaquet, M.D., Marseille; Jean-Pierre Louvet, M.D., Toulouse; Didier Dewailly, M.D., Lille; Patrick Roger, M.D., Bordeaux; Jean-Louis Schlienger, M.D., Strasbourg; Gèrard Schaison, M.D., Paris; Pierre Hartemann, M.D., Nancy.

Fertility and Sterility ◽

10.1016/s0015-0282(16)54779-7 ◽

1992 ◽

Vol 57 (1) ◽

pp. 74-80 ◽

Cited By ~ 9

Author(s):

Thierry Brue ◽

Ioana Lancranjan ◽

Jean-Pierre Louvet ◽

Didier Dewailly ◽

Patrick Roger ◽

...

Keyword(s):

Multicenter Study ◽

European Society ◽

Term Treatment ◽

Human Reproduction ◽

Joint Meeting ◽

Long Term Treatment ◽

Congress Organization ◽

Long Acting

Download Full-text

Donantes de ovocitos: análisis comparativo de dos muestras de Argentina y España sobre perfil de donantes, motivaciones y anonimato

Política y Sociedad ◽

10.5209/poso.59726 ◽

2019 ◽

Vol 56 (3) ◽

pp. 603-622

Author(s):

Natacha Salome Lima ◽

Consuelo Álvarez Plaza ◽

Carla Cubillos Vega

Keyword(s):

European Society ◽

Buenos Aires ◽

Human Reproduction ◽

Las Mujeres ◽

N 93

La ovodonación es el proceso por el cual una mujer dona óvulos a una clínica de reproducción asistida o a un banco de gametos con fines reproductivos (para una mujer receptora) o con la finalidad de utilizarlos para investigación biomédica. Los ciclos de tratamiento donde intervienen óvulos “donados” son cada vez más frecuentes en todo el mundo. España ocupa el primer lugar en Europa en donación de ovocitos de acuerdo a los datos de 2016 de la European Society of Human Reproduction and Embryology (ESHRE). En 2016 se realizaron en Argentina 13.823 ciclos de tratamiento, con 2709 transferencias de ovodonación (19,5%) (SAMeR, 2017). El presente estudio tiene como objetivo visibilizar los perfiles sociodemográficos de dos muestras de donantes de ovocitos de Argentina (n=93) y de España (n=49), las diferencias si es que existen, en las motivaciones que presentan las donantes para inscribirse en los programas de donación de ovocitos y sus actitudes hacia el anonimato. La metodología del estudio es cuantitativa, mientras que las inferencias han sido complementadas con investigaciones empíricas, literatura específica y la revisión de los textos normativos vigentes. El instrumento de recolección de datos ha sido un cuestionario administrado durante los meses de marzo a octubre de 2017 en tres clínicas de fertilidad (una de Ciudad de Buenos Aires y dos de Madrid). Se puede inferir de los resultados que además de las motivaciones económicas para convertirse en donantes de óvulos, existen motivos altruistas. El altruismo entiéndase como construcción retórica de las clínicas y los consentimientos informados, destinada a eludir la mera consideración mercantil. Si bien un gran porcentaje de las mujeres encuestadas no desea conocer a las personas nacidas de sus óvulos, la mayoría considera que las personas deben conocer el modo en que han sido engendradas.

Download Full-text

Investigation and treatment of premature ovarian insufficiency: A multi-disciplinary review of practice

Post Reproductive Health ◽

10.1177/2053369118811233 ◽

2018 ◽

Vol 24 (4) ◽

pp. 155-162 ◽

Cited By ~ 3

Author(s):

A Richardson ◽

SA Haridass ◽

E Ward ◽

J Ayres ◽

NE Baskind

Keyword(s):

Significant Variation ◽

Fragile X ◽

Treatment Options ◽

Human Reproduction ◽

Premature Ovarian Insufficiency ◽

Teaching Hospitals ◽

Thyroid Peroxidase ◽

Mineral Density ◽

Ovarian Insufficiency ◽

Long Term Follow Up

Objectives To assess compliance with the European Society for Human Reproduction and Embryology (ESHRE) guidelines on the investigation and management of women with premature ovarian insufficiency at the Leeds Teaching Hospitals NHS Trust (LTHT) and to determine whether this varies depending on the clinical setting in which the women present. Study design A retrospective review of all females diagnosed with premature ovarian insufficiency between 1 July 2016 and 30 June 2017, presenting to one of the following clinics: reproductive medicine, specialist menopause, general gynaecology, oncology long-term follow-up, general endocrinology or paediatric endocrinology. Main outcome measures Proportion of patients who had the necessary investigations performed and relevant treatment options discussed. Results 103 women were included in the study. Overall, 40.6% had a karyotype. Screening for the Fragile-X pre-mutation, thyroid peroxidase and 21-hydroxylase antibodies occurred in 7.4%, 11.1% and 13.6% of women, respectively. Only 35.9% had their bone mineral density measured. There was significant variation in the performance of a karyotype (p < 0.001) and thyroid peroxidase antibodies (p < 0.01) between the different clinical settings. Overall, lifestyle advice was offered to 30.1%. Estrogen replacement, contraception, fertility options and bone protection were discussed with 76.0%, 38.4%, 59.0% and 75.0%, respectively. Psychological support was offered to 25.2%. There was significant variation for all apart from contraception. Conclusion The investigation and treatment of women with premature ovarian insufficiency at the LTHT is not consistent with the ESHRE guidelines and requires improvement. Furthermore, there is significant variation in management depending on the department to which the patient initially presents.

Download Full-text